Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings results on February 12, 2026 that fell short of analyst expectations. The Healthcare company reported earnings per…
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings results on February 12, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $2.51, missing the consensus estimate of $2.65 by $0.14 per share. Revenue came in at $693.2M, beating the estimate of $689.9M.
Bio-Rad Laboratories's stock moved following the earnings release. The stock currently trades at $256.56 with a market capitalization of $8.5B.
Our Markets Team monitors market data, SEC filings, analyst actions, earnings releases, and corporate announcements to produce timely updates for investors.
Current market data
NYSE · BIO
$380.96
Up: +$3.00 · +0.79%
Live quote updated
Keep reading
institutional ·
analyst ·
analyst ·
analyst ·
